

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4074


TITLE: The Effects of Signaling Through the EGF Receptor System Upon  
Regulation of Growth in Human Mammary Epithelial Cells

PRINCIPAL INVESTIGATOR: Becky Worthylake

CONTRACTING ORGANIZATION: Universtiy of Utah  
Salt Lake City, Utah 84112

REPORT DATE: May 31, 1995

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950801 025

DTIC QUALITY INSPECTED 1

JK

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

<b>1. AGENCY USE ONLY (Leave blank)</b>	<b>2. REPORT DATE</b> 31 May 95	<b>3. REPORT TYPE AND DATES COVERED</b> Annual 15 May 94 - 14 May 95	
<b>4. TITLE AND SUBTITLE</b> The Effects of Signaling Through the EGF Receptor System Upon Regulation of Growth in Human Mammary Epithelial Cells			<b>5. FUNDING NUMBERS</b> DAMD17-94-J-4074
<b>6. AUTHOR(S)</b>  Becky Worthylake			
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Utah, Graduate School Room 310 Park Building Salt Lake City, Utah 84112			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>
<b>11. SUPPLEMENTARY NOTES</b>			
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for public release, distribution unlimited			<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 words)</b> The levels of the Human EGF Receptor (HER1) and the related receptors HER2,3, and 4 were examined in human mammary epithelial cells (HMEC's). When HMEC's are grown on plastic tissue culture dishes HER1 is expressed at high levels, while HER2 and HER4 are only expressed at low levels. No HER3 was detected. The expression of the various ligands to these receptors was examined. HMEC's express high levels of amphiregulin; moderate levels of TGF-alpha, HB EGF; and very low level of EGF and B cellulin. The effects of HER1 stimulation on the levels of HER2 were examined in both HMEC's and mouse fibroblasts. Addition of exogenous EGF leads to a decrease in the levels of HER2. This downregulation occurs in 3 hours, this, the mechanism appears to be post transcriptional			
<b>14. SUBJECT TERMS</b>  EGF Receptor, Breast Cancer, Mammary Epithelial Cells, TGF-alpha Neu, Heregulin			<b>15. NUMBER OF PAGES</b> 8
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified			<b>16. PRICE STATEMENT</b>
<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to **stay within the lines** to meet **optical scanning requirements**.

### Block 1. Agency Use Only (Leave blank).

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

<b>C</b> - Contract	<b>PR</b> - Project
<b>G</b> - Grant	<b>TA</b> - Task
<b>PE</b> - Program Element	<b>WU</b> - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

### Block 12b. Distribution Code.

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

X Where copyrighted material is quoted, permission has been obtained to use such material.

X Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
DTIC GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

*Betsy Workyake* 5/31/95  
PI Signature Date

## Table of Contents

1. Front cover
2. SF298
3. Foreword
4. Table of Contents
5. Introduction
6. Body
7. Conclusions
8. Appendix: Figures 1-3

## Introduction

Overexpression of the human EGF receptor (HER1) and HER2 are associated with human breast cancer. This aim of this proposal is to explore the relationship between misregulation of signaling through these receptors and the malignant transformation of human mammary epithelial cells in an *in vitro* cell culture system. Two methods of growing these cells in a physiologically relevant manner is on semipermeable membranes or on a synthetic basement membrane. These culture systems allow the formation of polarized epithelial cells. On the basement membrane these structures resemble the alveoli and connecting ducts found in the mature mammary gland. The intracellular trafficking patterns of the EGF receptor play an important role in attenuation of the mitogenic signal transduced through this receptor. I will determine if perturbing the intracellular trafficking of the EGF and/or HER2 results in abnormal growth of human mammary epithelial cells in culture.

First, I will define the expression levels of HER1 and HER2 in normal human mammary epithelial cells by Western Blot and RT-PCR. Additionally, I will determine the role of trafficking in regulating the half life of these receptors by standard pulse chase procedures. Finally, these normal trafficking patterns will be altered either by introducing an EGF receptor trafficking mutant or by overexpressing the HER1 or HER2. The regulation of growth and organization in cells misregulating the EGF receptor signaling system will be assessed by proliferation assays and microscopy.

## Body

The levels of the Human EGF Receptor (HER1) and the related receptors HER2,3 and 4 were examined in human mammary epithelial cells (HMEC's) by Western blot. When HMEC's are grown on plastic tissue culture dishes HER1 is expressed at high levels, while HER2 and HER4 are only expressed at low levels. No HER3 was detected. Interestingly, the level of HER1 decreased dramatically when grown on semipermeable membranes, or on a synthetic basement membrane. Unexpectedly, the level of HER2 also decreased, but only 3-4 fold as compared to 10 fold downregulation for HER1. The level of HER4 was low whether the cells were cultured on plastic or on membranes; however, on plastic HER4 protein runs as a doublet, while on membranes only the faster mobility band is expressed. (See figure 1)

The expression of the various ligands to these receptors was examined by RT PCR, by others in the laboratory. HMEC's express high levels of amphiregulin; moderate levels of TGF-alpha, Heparin binding (HB) EGF; and very low levels of EGF and  $\beta$  cellulin. There is no known ligand for HER2, but heregulin is a ligand for both HER3 and HER4 which heterodimerize with HER2. RT PCR demonstrates that the HMEC cells express significant levels of heregulin. (See figure 2)

The effects of HER1 stimulation on the levels of HER2 were examined in both HMEC's and mouse fibroblasts. Addition of exogenous EGF leads to a decrease in the levels of HER2 as assessed by Western blot. This downregulation occurs in 3 hours, thus, the mechanism appears to be post transcriptional. Since our laboratory has mouse fibroblast cell lines containing many mutants of the HER1, I have pursued the mechanism of HER1 stimulation on HER2 trafficking in the fibroblast cell line. A HER1 construct harboring a point mutation in the kinase domain, rendering it kinase inactive. Interestingly, stimulation of this HER1 mutant with exogenous EGF also leads to a downregulation in the level of HER2. (See figure 3)

## Conclusions

### 1. HER expression levels:

a. HER1 is expressed at high levels in HMEC growing on plastic, but is dramatically reduced upon culturing on membranes or a synthetic basement membrane.

b. HER2 is expressed at a low level in HMEC growing on plastic, and its expression is further reduced by culturing on membranes.

c. HER3 could not be detected in HMEC grown on plastic or on a membrane.

d. HER4 is expressed at a low level in HMEC cultured on plastic or membranes. Interestingly, it is expressed as a doublet on plastic, but only a single band when grown on membranes.

### 2. HER ligand expression:

a. Several HER1 ligands are expressed in HMEC's: Amphiregulin is abundant, TGF-alpha and HB EGF are moderately expressed, and EGF and  $\beta$  Cellulin are rare.

b. The ligand for HER3 and HER4, heregulin, is expressed at significant levels in HMEC's.

### 3. Effects of HER1 stimulation on the trafficking of HER2:

a. Addition of exogenous EGF to stimulate HER1 results in the downregulation of HER2 levels.

b. This downregulation occurs within 3 hours and is thought to be post transcriptional.

c. A kinase negative mutant of HER1 retains the ability to downregulate HER2 in response to EGF.

Four mechanisms by which EGF stimulation of HER1 could lead to a downregulation in the level of HER2:


1. Heterodimerization followed by co-internalization
2. Transphosphorylation of HER2 by HER1, leading to HER2 activation and internalization
3. Heterodimerization directly activated HER2, leading to its internalization
4. Signaling through HER1 leads to transcriptional repression of HER2 mRNA

The fourth mechanism can be ruled out by the time course shows that the downregulation occurs within 3 hours. The second mechanism can also be ruled out because a kinase negative version of HER1 is capable of reducing HER2 levels in response to EGF. Distinguishing between mechanisms 1 and 3 can be differentiated by determining if a HER1 mutant which lacks the whole cytoplasmic tail of the receptor can downregulate the levels of HER2 in response to EGF. This truncation mutant of HER1 is unable to be internalized in response to EGF, yet is reported to retain the ability to heterodimerize with HER2. Thus, if this truncated receptor can reduce the levels of HER2, then the two receptors are not co-internalized and heterodimerization can directly activate HER2, leading to its internalization.




Appendix

Figure 1: Western blot showing expression levels of HER's in HMEC's




HMEC's were cultured for 7 days on plastic tissue culture dishes (P) or permeable membranes (M). Cells extracts were separated on SDS PAGE and Western blotted for the various receptors.

Figure 2: RT PCR analysis of Heregulin expression in HMEC's




RNA was isolated from HMEC's and mouse fibroblasts using TRI REAGENT. The RNA was then subjected to RT-PCR in the presence of <sup>32</sup>P-dCTP using primers specific to heregulin. The resulting products were analyzed by autoradiography.

Figure 3: Western blot analysis of HER2 levels in response to EGF



Quantitation of Western analysis of HER2 levels in fibroblasts in an EGF timecourse



Cells were treated with 100ng/ml EGF for 3 days. Cell extracts were then analyzed by Western blot with HER2 antibody as a probe. Results were quantitated by phosphorimager analysis.

AD \_\_\_\_\_

GRANT NO: DAMD17-94-J-4074

TITLE: The Effects of Signaling Through the EGF Receptor System Upon  
Regulation of Growth in Human Mammary Epithelial Cells

PRINCIPAL INVESTIGATOR: Becky Worthylake

CONTRACTING ORGANIZATION: Universtiy of Utah  
Salt Lake City, Utah 84112

REPORT DATE: May 31, 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

31 May 95

Annual 15 May 94 - 14 May 95

The Effects of Signaling Through the EGF Receptor System  
Upon Regulation of Growth in Human Mammary Epithelial  
Cells

DAMD17-94-J-4074

Becky Worthylake

University of Utah, Graduate School  
Room 310 Park Building  
Salt Lake City, Utah 84112

U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

Approved for public release, distribution unlimited

The levels of the Human EGF Receptor (HER1) and the related receptors HER2,3, and 4 were examined in human mammary epithelial cells (HMEC's). When HMEC's are grown on plastic tissue culture dishes HER1 is expressed at high levels, while HER2 and HER4 are only expressed at low levels. No HER3 was detected. The expression of the various ligands to these receptors was examined. HMEC's express high levels of amphiregulin; moderate levels of TGF-alpha, HB EGF; and very low level of EGF and B cellulin. The effects of HER1 stimulation on the levels of HER2 were examined in both HMEC's and mouse fibroblasts. Addition of exogenous EGF leads to a decrease in the levels of HER2. This downregulation occurs in 3 hours, this, the mechanism appears to be post transcriptional

8

EGF Receptor, Breast Cancer, Mammary Epithelial Cells, TGF-alpha  
Neu, Heregulin

Unclassified

Unclassified

Unclassified

Unlimited

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

X Where copyrighted material is quoted, permission has been obtained to use such material.

X Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Betty Worklake 5/31/95  
PI Signature Date

## Table of Contents

1. Front cover
2. SF298
3. Foreword
4. Table of Contents
5. Introduction
6. Body
7. Conclusions
8. Appendix: Figures 1-3

## Introduction

Overexpression of the human EGF receptor (HER1) and HER2 are associated with human breast cancer. This aim of this proposal is to explore the relationship between misregulation of signaling through these receptors and the malignant transformation of human mammary epithelial cells in an *in vitro* cell culture system. Two methods of growing these cells in a physiologically relevant manner is on semipermeable membranes or on a synthetic basement membrane. These culture systems allow the formation of polarized epithelial cells. On the basement membrane these structures resemble the alveoli and connecting ducts found in the mature mammary gland. The intracellular trafficking patterns of the EGF receptor play an important role in attenuation of the mitogenic signal transduced through this receptor. I will determine if perturbing the intracellular trafficking of the EGF and/or HER2 results in abnormal growth of human mammary epithelial cells in culture.

First, I will define the expression levels of HER1 and HER2 in normal human mammary epithelial cells by Western Blot and RT-PCR. Additionally, I will determine the role of trafficking in regulating the half life of these receptors by standard pulse chase procedures. Finally, these normal trafficking patterns will be altered either by introducing an EGF receptor trafficking mutant or by overexpressing the HER1 or HER2. The regulation of growth and organization in cells misregulating the EGF receptor signaling system will be assessed by proliferation assays and microscopy.

## Body

The levels of the Human EGF Receptor (HER1) and the related receptors HER2,3 and 4 were examined in human mammary epithelial cells (HMEC's) by Western blot. When HMEC's are grown on plastic tissue culture dishes HER1 is expressed at high levels, while HER2 and HER4 are only expressed at low levels. No HER3 was detected. Interestingly, the level of HER1 decreased dramatically when grown on semipermeable membranes, or on a synthetic basement membrane. Unexpectedly, the level of HER2 also decreased, but only 3-4 fold as compared to 10 fold downregulation for HER1. The level of HER4 was low whether the cells were cultured on plastic or on membranes; however, on plastic HER4 protein runs as a doublet, while on membranes only the faster mobility band is expressed. (See figure 1)

The expression of the various ligands to these receptors was examined by RT PCR, by others in the laboratory. HMEC's express high levels of amphiregulin; moderate levels of TGF-alpha, Heparin binding (HB) EGF; and very low levels of EGF and  $\beta$  cellulin. There is no known ligand for HER2, but heregulin is a ligand for both HER3 and HER4 which heterodimerize with HER2. RT PCR demonstrates that the HMEC cells express significant levels of heregulin. (See figure 2)

The effects of HER1 stimulation on the levels of HER2 were examined in both HMEC's and mouse fibroblasts. Addition of exogenous EGF leads to a decrease in the levels of HER2 as assessed by Western blot. This downregulation occurs in 3 hours, thus, the mechanism appears to be post transcriptional. Since our laboratory has mouse fibroblast cell lines containing many mutants of the HER1, I have pursued the mechanism of HER1 stimulation on HER2 trafficking in the fibroblast cell line. A HER1 construct harboring a point mutation in the kinase domain, rendering it kinase inactive. Interestingly, stimulation of this HER1 mutant with exogenous EGF also leads to a downregulation in the level of HER2. (See figure 3)

## Conclusions

### 1. HER expression levels:

a. HER1 is expressed at high levels in HMEC growing on plastic, but is dramatically reduced upon culturing on membranes or a synthetic basement membrane.

b. HER2 is expressed at a low level in HMEC growing on plastic, and its expression is further reduced by culturing on membranes.

c. HER3 could not be detected in HMEC grown on plastic or on a membrane.

d. HER4 is expressed at a low level in HMEC cultured on plastic or membranes. Interestingly, it is expressed as a doublet on plastic, but only a single band when grown on membranes.

### 2. HER ligand expression:

a. Several HER1 ligands are expressed in HMEC's: Amphiregulin is abundant, TGF-alpha and HB EGF are moderately expressed, and EGF and  $\beta$  Cellulin are rare.

b. The ligand for HER3 and HER4, heregulin, is expressed at significant levels in HMEC's.

### 3. Effects of HER1 stimulation on the trafficking of HER2:

a. Addition of exogenous EGF to stimulate HER1 results in the downregulation of HER2 levels.

b. This downregulation occurs within 3 hours and is thought to be post transcriptional.

c. A kinase negative mutant of HER1 retains the ability to downregulate HER2 in response to EGF.

Four mechanisms by which EGF stimulation of HER1 could lead to a downregulation in the level of HER2:


1. Heterodimerization followed by co-internalization
2. Transphosphorylation of HER2 by HER1, leading to HER2 activation and internalization
3. Heterodimerization directly activated HER2, leading to its internalization
4. Signaling through HER1 leads to transcriptional repression of HER2 mRNA

The fourth mechanism can be ruled out by the time course shows that the downregulation occurs within 3 hours. The second mechanism can also be ruled out because a kinase negative version of HER1 is capable of reducing HER2 levels in response to EGF. Distinguishing between mechanisms 1 and 3 can be differentiated by determining if a HER1 mutant which lacks the whole cytoplasmic tail of the receptor can downregulate the levels of HER2 in response to EGF. This truncation mutant of HER1 is unable to be internalized in response to EGF, yet is reported to retain the ability to heterodimerize with HER2. Thus, if this truncated receptor can reduce the levels of HER2, then the two receptors are not co-internalized and heterodimerization can directly activate HER2, leading to its internalization.




### Appendix

Figure 1: Western blot showing expression levels of HER's in HMEC's




HMEC's were cultured for 7 days on plastic tissue culture dishes (P) or permeable membranes (M). Cells extracts were separated on SDS PAGE and Western blotted for the various receptors.

Figure 2: RT PCR analysis of Heregulin expression in HMEC's




RNA was isolated from HMEC's and mouse fibroblasts using TRI REAGENT. The RNA was then subjected to RT-PCR in the presence of <sup>32</sup>P-dCTP using primers specific to heregulin. The resulting products were analyzed by autoradiography.

Figure 3: Western blot analysis of HER2 levels in response to EGF



Quantitation of Western analysis of HER2 levels in fibroblasts in an EGF timecourse



Cells were treated with 100ng/ml EGF for 3 days. Cell extracts were then analyzed by Western blot with HER2 antibody as a probe. Results were quantitated by phosphorimager analysis.